Following U.S. Stocks are among the “Top Gainers” during an Early trade Tuesday: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Geron Corporation (NASDAQ:GERN)
CASI Pharmaceuticals Inc (NASDAQ:CASI) skyrocketed 34.41% in an early trade and is now trading at $1.68. The company holds the market capitalization of 47.26M. The stock return on equity value is -259.10%, while return on assets value is -195.70%. Its 20-day moving average gained 11.03%, and the stock moved above 50-day moving average of 14.37%.
Formerly on March 4, CASI Pharmaceuticals, Inc. (CASI), declared the selection of Rong Chen MD, Ph.D. as Chief Medical Officer. Dr. Chen brings to CASI over 20 years of experience in the areas of pharmaceutical clinical development and regulatory affairs. He will report to Dr. Ken K. Ren, Ph.D., CASI’s Chief Executive Officer.
Earlier to joining CASI, Dr. Chen was Area Medical Director and Chief Medical Governance Officer at GSK China/Hong Kong Area and in 2010 was promoted to VP, Head of Regulatory Center of Excellence, Corporation Representative having overall responsibility for the registration of drug and vaccine products. Preceding to GSK, Dr. Chen was Medical Director, Global Medical Expert at Bayer-Schering Pharma Asia Pacific Area and from 2001-2005 was Medical Director at Sanofi China. Dr. Chen was co-author of various published articles and has presented at many international conferences. Dr. Chen received his medical degree from Shandong Medical University, China and received his Ph.D. in Clinical Pharmacology from the Royal Adelaide Hospital, University of Adelaide, Australia in 1989.
Dr. Chen stated, “I am very excited to be part of the corporation’s team to advance the research and clinical development of its growing pipeline of drugs for cancer and other unmet medical needs. I look forward to leading the effort to successfully develop them and to bring them to patients. This is a very exciting time to join the CASI family and I look forward to working with the team to achieve the many milestones to come.”
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical corporation, develops therapeutics to treat cancer and other diseases primarily in the United States and China.
On the other hand, Geron Corporation (NASDAQ:GERN) picked up 12.84% in an early trade and is now trading at $4.13. The stock has the beta value of 2.11, and its volatility for the week is 13.16%, while for the month it is 6.23%. The company has the market capitalization of $602.26M. The mean recommendation of analysts for this stock is 2.50.(where 1=Buy, 5=Sale).
Geron Corporation (NASDAQ:GERN), a clinical stage biopharmaceutical corporation, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The corporation was founded in 1990 and is based in Menlo Park, California.
